Hepamerz%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252528l-Ornithine%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520l-Aspartate%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520-%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252520lola%2525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252525252529

## HepaMerz (l-ornithine l-aspartate) ### Overview HepaMerz is a combination of two amino acids, l-ornithine and l-aspartate, used in the management of hyperammonemia, particularly in patients with liver insufficiency. It is believed to promote ammonia detoxification by stimulating the urea cycle and glutamine synthesis. ### Primary Indications * Treatment of latent and overt hepatic encephalopathy. ### Adult Dosing * **Oral:** 3 sachets (18 g total) per day, divided into three doses. A typical dose is 6 g of l-ornithine l-aspartate per dose. * **Intravenous (IV):** 10-20 g per day by infusion over 30-60 minutes. A typical dose is 5 g l-ornithine l-aspartate per infusion bag. Dosing may be adjusted based on patient response and severity of hepatic encephalopathy. ### Pediatric Dosing * Dosing for pediatric patients is not well-established. Caution and individualized dosing based on clinical judgment are recommended. ### Dose Adjustments * No specific dose adjustments are typically required for renal impairment, as the drug is primarily metabolized and excreted by the liver. However, caution is advised in severe renal impairment. ### Contraindications * Severe hypersensitivity to l-ornithine l-aspartate or any component of the formulation. * Severe kidney disease (marked by reduced urine output or elevated creatinine). ### Adverse Effects * Gastrointestinal disturbances such as nausea, vomiting, and abdominal pain are the most common side effects. * Rarely, rash or pruritus may occur. ### Key Drug Interactions * No significant drug interactions have been widely reported. However, potential additive effects with other medications affecting ammonia levels or liver function should be considered. ### Monitoring * Monitor for clinical improvement in symptoms of hepatic encephalopathy (e.g., confusion, asterixis). * Monitor serum ammonia levels, though this may not always correlate directly with clinical improvement. * Monitor renal function, especially in patients with pre-existing kidney issues or those receiving high doses. ### Clinical Pearls * HepaMerz is most effective when administered early in the course of hepatic encephalopathy. * It can be used as an adjunct to other standard therapies for liver disease and hepatic encephalopathy. * The oral formulation is available in sachets containing 6 g of l-ornithine l-aspartate. *** **Disclaimer:** This information is intended for healthcare professionals. Always consult the most current prescribing information and product literature for complete details and to verify dosage and safety information before administering any medication. Local institutional protocols may also dictate specific dosing regimens.